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Abstract Deuterated choline-d9 labelling of IMR-32 cells en-
abled comparison of the molecular speci¢cities of whole cell and
endonuclear phosphatidylcholine synthesis after 96 h polyunsat-
urated fatty acid supplementation. Surprisingly, while cell phos-
phatidylcholine synthesis and remodelling re£ected a pattern of
polyunsaturated fatty acid accretion, the saturated endonuclear
phosphatidylcholine pool was only transiently labelled with poly-
unsaturates. Periodic endonuclear accumulations of the lipid
second messenger diacylglycerol, mobilised from unsaturated
phosphatidylinositol or saturated phosphatidylcholine, accom-
pany cell proliferation. Non-speci¢c incorporation into endonu-
clear phosphatidylcholine and selective removal or remodelling
of unsaturated molecular species may form part of a single ‘o¡
switch’ recycling all endonuclear diacylglycerol accumulations.
* 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Unlike cells in vivo, where homeostatic mechanisms actively
resist change in phospholipid composition [1], cultured cells
progressively lose capacity to counter the external manipula-
tion of membrane phospholipid molecular species. For phos-
phatidylcholine (PtdCho), remodelling mechanisms involving
the sequential actions of phospholipases and speci¢c lyso
PtdCho acyl transferases augment any synthetic speci¢city
de novo to yield characteristic membrane composition [2].
An extensive literature de¢nes the e¡ects of fatty acid supple-
mentation upon these parameters [3^6]. So, for example, HL-
60 cells cultured in the presence of unsaturated and polyun-
saturated fatty acid (PUFA), for 4 days at 30 WM, preferen-
tially incorporate exogenous fatty acid into selected PtdCho
molecular species, thereby increasing their fractional represen-
tation [7]. However, it is unclear to what extent specialised
sub-cellular phospholipid compartments such as that in the
nuclear matrix [8^11] may preserve composition [12] irrespec-
tive of bulk membrane variation.
In IMR-32 neuroblastoma cells, highly puri¢ed nuclei sup-
port autonomous PtdCho synthesis de novo [12] that is re-
sponsible for around 6% of whole cell PtdCho. Unlike bulk
PtdCho, synthesised on the ER, endonuclear PtdCho retains
more than 60% disaturated molecular species [12]. Several
functional rationales may underpin the pattern of saturated
endonuclear PtdCho synthesis [12] and a catalytically active,
endonuclear isoform of CTP:phosphocholine cytidylyl trans-
ferase (CCTK) is essential for the survival of proliferating cells
[13], con¢rming the pathway’s pivotal role in growth and
division. Indeed, export and caspase-mediated degradation
of CCTK accompanies apoptosis [14] consistent with endonu-
clear capacity for PtdCho synthesis mandating cell viability.
Hydrolysis of endonuclear PtdCho and phosphatidylino-
sitol (PtdIns) provide the periodic diacylglycerol (DAG)
accumulations that accompany cell proliferation [11]. Con-
sequently, in growing cells with progressive endonuclear
phospholipid accretion, endonuclear DAG composition is de-
termined by signalling-related accumulations from highly sa-
turated PtdCho or highly polyunsaturated PtdIns [11] togeth-
er with the products of lipid phosphate phosphatase action on
phosphatidic acid and any DAG synthesis de novo. With no
proven endonuclear PtdIns synthesis, the downstream fate of
polyunsaturated DAG formed by hydrolysis of PtdIns is un-
certain but may in principle be accessible for incorporation
into PtdCho. However, while remodelling of newly synthe-
sised mono- and di-unsaturated endonuclear PtdCho increases
saturation [12], the concurrent depletion of PUFA-containing
species [12] may also indicate the operation of a molecular
selectivity mechanism that precludes PUFA^DAG incorpora-
tion into endonuclear PtdCho. Tandem electrospray ionisa-
tion mass spectrometry (ESI-MS) following 9 deuterated
methyl choline (choline-d9) labelling [12,15] enables endonu-
clear PtdCho metabolism to be probed with unparalleled spec-
i¢city and sensitivity. Here we compare whole cell and endo-
nuclear PtdCho synthesis speci¢city in the face of prolonged,
elevated PUFA exposure.
2. Materials and methods
2.1. Materials
Arachidonic acid (AA, 20:4 n-6), docosahexaenoic acid (DHA, 22:6
n-3) and fatty acid-free albumin were purchased from Sigma-Aldrich.
Deuterated choline (choline-d9) was purchased from C/D/N Isotopes
(Pointe-Claire, QC, Canada). Tissue culture plasticware and reagents
were from Life Technologies (Paisley, UK). Varian Bond Elut amino-
propyl (NH2) solid phase extraction columns were supplied by Phe-
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nomenex (Maccles¢eld, Cheshire, UK). Chemicals and biochemicals
were from Merck (Lutterworth, Leicestershire, UK) or Sigma-Aldrich
(Poole, Dorset, UK).
2.2. Methods: IMR-32 cell culture, fatty acid supplementation and
preparation of nuclei
IMR-32 human neuroblastoma cells were cultured as described pre-
viously [12]. Fatty acid supplements were prepared at 3 mM (U100
concentration) coupled to fatty acid-free albumin at a 2:1 molar ratio
in Hank’s balanced salt solution without Caþþ/Mgþþ adjusted to pH
7.0 and ¢lter sterilised through 0.2 Wm ¢lters. For supplementation
experiments cells were trypsinised and plated 24 h prior to commenc-
ing fatty acid exposure. Both supplemented and control culture media
were refreshed at 48 h. Seeding densities were chosen to ensure that
cells with the highest recorded growth at 96 h remained sub-con£uent.
Whole cell and membrane-free nuclear fractions were prepared exactly
as described previously [12].
2.3. Deuterated choline labelling of cells
Newly synthesised PtdCho in whole cells and nuclei was determined
after 3 h incubation of whole cells with excess choline-d9 [12].
2.4. PtdCho puri¢cation and mass spectrometric analysis
Following the introduction of PtdCho 14:0/14:0 internal standard
as described [12], chloroform/methanol extraction and solid-phase
NH2 column puri¢cation, the PtdCho fraction was analysed by
ESI-MS using a Quatro Ultima triple quadrupole mass spectrometer
(Micromass, Wytheshaw, UK). Endogenous PtdCho was selectively
determined by precursor scans of the phosphocholine fragment (m/z
+184), while newly synthesised PtdCho was determined by equivalent
precursor scans of the d9-phosphocholine fragment (m/z +193) [12].
To account for previously reported decrease in response with increas-
ing m/z values [16], a formula for correcting reduced response was
determined experimentally as: a=2U1013b33:9873, where a= reduced
response factor relative to a value of 1.00 for PtdCho14:0/14:0 and
b=m/z value. The formula was constructed following triplicate parent
scan analyses of equimolar PtdCho 14:0/14:0 plus seven other
PtdCho molecular species (saturated, monounsaturated and diunsatu-
rated) covering the full m/z range reported at four di¡erent concen-
trations over a 1000-fold span. MS/MS responses were calibrated
daily using this mix. The di¡erential fragmentation of PUFA-contain-
ing species [17], which can result in signi¢cant overestimation at high
concentration [17], did not dramatically confound here, probably due
to the very low PtdCho concentrations demanded by endonuclear
phospholipid analyses. Whole cell PtdCho concentrations were rou-
tinely diluted to give similar total ion intensities to those achieved
with corresponding nuclear fractions, and comparison of m/z+184
parent scans with total positive scans over the same m/z range showed
no dramatic discrimination of any molecular species. It was not pos-
sible to determine these parameters for d9-choline containing PtdCho
species. These were consequently assumed to behave as their normal
choline analogues.
2.5. Cell proliferation assays
Cell proliferation assays were performed in 96-well, £at-bottomed
tissue culture plates using the CellTiter 96 aqueous One solution cell
proliferation assay (Promega) with initial seeding densities chosen
empirically to span the full dynamic range of the kit after 96 h.
3. Results and discussion
3.1. E¡ect of fatty acid supplementation upon cell proliferation
and membrane PtdCho synthesis
To exclude the possibility of PUFA-mediated derangement
of cell-growth rates and associated membrane synthesis we
¢rst established that prolonged PUFA supplementation
(30 WM for 96 h) did not dramatically alter proliferation or
PtdCho synthesis (Fig. 1).
Control cell counts increased 3^4-fold while remaining sub-
con£uent over 96 h, in agreement with cell counts at trypsi-
nisation (control cell growth is shown as 100% at each time
point). After 24 h PUFA supplementation cell proliferation
was diminished compared with controls, but by 72 h was
comparable in each group and over the ¢nal 24 h increased
in PUFA-treated cells (Fig. 1a). Membrane accretion and cell
proliferation are intimately associated [18], so any PtdCho
increase in cultured cells will represent the balance of new
synthesis and degradation. The proportion of whole cell
PtdCho synthesis over 3 h was estimated by ratioing total
ion counts from precursor scans of m/z+193 with those of
precursor scans of m/z+184 [12]. Control synthesis over 3 h
was 7.92Q 3.95% (meanQS.D., n=4) while the corresponding
¢gure following AA- and DHA-supplementation were
6.61Q 4.42% (meanQS.D., n=6) and 8.45Q 4.20% (meanQ
S.D., n=6), respectively. Extrapolation of the mean 3-h-syn-
thetic rates to a full 96 h of culture (Fig. 1b) showed a cumu-
lative choline £ux through PtdCho synthesis more than dou-
ble that required simply for growth-related membrane
biogenesis. While these results provide evidence for extensive
choline headgroup turnover under all experimental condi-
tions, they also suggest that fatty acid supplementation for
96 h had no dramatic a¡ect either on IMR-32 cell growth
or the rate of PtdCho synthesis.
3.2. Whole cell PtdCho composition and synthesis following
PUFA supplementation
The molecular species compositions of control cell PtdCho
Fig. 1. E¡ect of PUFA supplementation on IMR-32 cell growth
and PtdCho synthesis. a: Cell proliferation relative to sub-con£uent
control (non-PUFA-treated) cultures was determined at 24, 48, 72
and 96 h following supplementation with 30 WM PUFA and with
one complete medium change at 48 h. Data presented represents
meansQS.D. (n=4^6 for each time point). b: Projected cumulative
choline £uxes through PtdCho for control and PUFA-treated cells
over 96 h PUFA supplementation derived by extrapolating mean 3 h
PtdCho-synthesis rates at 96 h.
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and corresponding newly synthesised pools after 3 h incuba-
tion with choline-d9 (Fig. 2a, d) were essentially identical to
those seen previously [12]. Newly synthesised PtdCho compo-
sition resembled the endogenous pool, but further tailoring
was obvious from the equilibrium composition. For example,
PtdCho 16:0/18:1 was more abundant in newly synthesised
cell PtdCho (Fig. 2d) than in endogenous PtdCho (Fig. 2a),
suggesting the operation of post-synthesis acyl remodelling.
However, despite minor variation, a lack of change in total
PUFA-containing PtdCho between newly synthesised and
equilibrium compositions suggests only slight involvement of
these species in the remodelling.
Following prolonged PUFA supplementation, cells toler-
ated a wide variation in the molecular species compositions
of their endogenous PtdCho, with increased concentrations of
unsaturated species after both AA (Fig. 2b) and DHA (Fig.
2c) supplementation. In both cases, the sn-1 palmitoyl (16:0),
sn-2 PUFA was the species most elevated. After AA-supple-
mentation PtdCho 16:0/20:4 content increased from the con-
trol value of 7.2 Q 0.7% (meanQS.D., n=4) to 12.5Q 1.6%
(meanQS.D., n=6) while DHA-supplementation increased
the content of PtdCho 16:0/22:6 from 3.2Q 1.2% (meanQ
S.D., n=4) to 8.9Q 2.2% (meanQS.D., n=6). Despite some
small relative changes within the disaturated species their total
proportion did not vary between any of the groups.
The pattern of newly synthesised cell PtdCho data follow-
ing supplementation was even more enriched in unsaturated
species that that observed in the equilibrium composition. For
both AA and DHA supplementation, the sn-1 16:0, sn-2
PUFA supplanted PC16:0/18:1 as the dominant species syn-
thesised (Fig. 2e, f) with sn-1 oleoyl (18:1), sn-2 PUFA and
sn-1, sn-2 di-PUFA enrichments also noted. For example,
while newly synthesised PC16:0/20:4 in control cells repre-
sented 8.7Q 2.3% (meanQS.D., n=4) this increased to
18.0Q 3.5% (meanQS.D., n=6) upon supplementation with
30 WM AA for 96 h. Likewise PtdCho 16:0/22:6 comprised
4.2Q 1.0% (meanQS.D., n=4) of newly synthesised PtdCho
in control cells, but rose to 15.2Q 4.9% (meanQS.D., n=6)
following DHA supplementation. The fractional synthetic
rates of both these species were considerably greater than their
equilibrium concentrations after supplementation of 12.5Q
1.6% (meanQS.D., n=6) and 8.9Q 2.2% (meanQS.D., n=6),
respectively. Clearly, the post-3-h labelling change following
PUFA supplementation suggests that remodelling here in-
volves degradation of the whole PUFA-containing PtdCho
rather than simply remodelling the sn-2 position [7]. In addi-
tion, the wide range of molecular species incorporated into
newly synthesised PtdCho demonstrates a lack of molecular
speci¢city in whole cell PtdCho synthesis de novo. The bio-
logically accessible DAG pool determines newly synthesised
PtdCho composition and prolonged PUFA exposure has en-
riched the representation of PUFA-containing DAG. Down-
stream remodelling/degradation then produces characteristic
whole tissue or subcellular membrane divergence in PtdCho
composition.
3.3. Endonuclear PtdCho composition and synthesis following
PUFA supplementation
The highly saturated endonuclear PtdCho pool [12] from
the same cell cultures showed some remarkable composition
Fig. 2. ESI-MS of PtdCho from control, AA-supplemented and DHA-supplemented whole IMR-32 cells after 3 h incubation with choline-d9.
Each panel depicts diagnostic precursor scans of the phosphocholine headgroup (m/z+184, a, b and c) showing endogenous PtdCho or of the
phosphocholine-d9 headgroup (m/z+193, d, e and f) showing newly synthesised PtdCho. Panels a and d are scans from control cells, while pan-
els b and e and panels c and f are from AA-supplemented and DHA-supplemented cells, respectively.
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and synthesis di¡erences. Speci¢cally, endogenous endonu-
clear PtdCho compositions (Fig. 3a^c) showed that the highly
saturated species were tightly retained, even after 96 h PUFA
supplementation. However, in both cases the sn-1 16:0, sn-2
PUFA rose from below quanti¢able level to 3.2Q 0.4%
(meanQS.D., n=6) for PtdCho 16:0/20:4 in AA-treated cells
and 2.2 Q 0.5% (meanQS.D., n=6) for PtdCho 16:0/22:6 in
DHA-treated cells. Given the synthesis patterns below, small
PUFA enrichments at equilibration are most easily explained
as representative of the balance of new synthesis and active
remodelling or degradation or possibly export from the nu-
cleus. The turnover rates of endonuclear, PUFA-containing
PtdCho might resolve this issue but are not accessible from
these data. Alternatively highly puri¢ed nuclei may be able to
tolerate small proportions of PUFA-containing PtdCho spe-
cies but not those higher ¢gures seen in the whole cell. The
patterns of endonuclear PtdCho synthesis de novo seen below
(Fig. 3d^f) would support either possibility.
Newly synthesised endonuclear PtdCho in control cells fol-
lowed the pattern previously seen [12]. There was no apparent
synthesis of PUFA-containing species, and the degree of sat-
uration enrichment increased from newly synthesised (Fig. 3d)
to the equilibration composition of PtdCho (Fig. 3a). In
agreement with our previous report [12], this remodelling of
newly synthesised, largely saturated PtdCho into even more
saturated species represented the major endonuclear transfor-
mation in control cells [12]. By contrast, PUFA supplementa-
tion of cells stimulated the synthesis within the nucleus of
signi¢cant amounts of PtdCho containing PUFA (Fig. 3e,
f). For the predominant species this represented 12.9Q 3.0%
(meanQS.D., n=6) for PtdCho 16:0/20:4 in AA-supple-
mented cells and 9.8Q 3.8% (meanQS.D., n=6) for PtdCho
16:0/22:6 in DHA-supplemented cells. However, the large
synthetic enrichments in PUFA-containing species were not
carried forward to the corresponding endonuclear equilibrium
compositions (Fig. 3b, c). Examination of the endonuclear
ESI-MS traces suggests that removing PUFA-containing
PtdCho solely by remodelling the sn-2 position would require
signi¢cant re-acylation with monounsaturated species to re-
tain constant endonuclear PtdCho saturation. The predomi-
nance of endonuclear 16:0 CoA [19] and preference for 16:0
acylation in this compartment [20] provides limited scope for
such remodelling, and its operation on this scale would still
require an as yet uncharacterised rapid removal route for lib-
erated PUFA. Indeed, the data suggest instead that complete
degradation/removal of PUFA-containing species from the
nucleus contributes to maintaining the pattern of saturation
enrichment. In either case, the lack of speci¢city of endonu-
clear PtdCho synthesis at the level of DAG incorporation,
unlike that of whole cell, is e¡ectively countered by the selec-
tive removal of PUFA-containing species between synthesis
and the establishment of the equilibrium composition.
3.4. Comparison of molecular speci¢cities and implications
While both pathways showed a lack of selectivity for DAG
incorporation into newly synthesised PtdCho (Figs. 2 and 3),
post-synthetic tailoring of the lipid was more tightly regulated
in the endonuclear compartment (Fig. 3), as evidenced by
retention of highly saturated PtdCho. The maintenance of
highly saturated endonuclear PtdCho is likely related to es-
Fig. 3. ESI-MS of PtdCho from highly puri¢ed control, AA-supplemented and DHA-supplemented IMR-32 nuclei after 3 h incubation with
choline-d9. Each panel depicts diagnostic precursor scans of the phosphocholine headgroup (m/z+184, a, b and c) showing endogenous PtdCho
or of the phosphocholine-d9 headgroup (m/z+193, d, e and f) showing newly synthesised PtdCho. Panels a and d are scans from control cells,
while panels b and e and panels c and f are from AA-supplemented and DHA-supplemented cells, respectively.
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sential functional requirements as noted previously [12]. How-
ever, lack of stringency in terms of DAG incorporation into
endonuclear PtdCho provides the synthetic pathway with a
potential role in the universal termination of DAG-mediated
endonuclear signalling. Periodic accumulations of predomi-
nantly saturated or unsaturated endonuclear DAG arise
from PtdCho or PtdIns, respectively [11]. However, while a
partial function of endonuclear PtdCho synthesis may be to
remove and recycle the PtdCho-derived lipid second messen-
ger [12], no comparable system exists for regenerating endo-
nuclear PtdIns. The nucleus converts PtdIns to the higher
phosphorylated forms, PtdInsP and PtdInsP2, necessary for
IP3 and DAG liberation, but the pathway for PtdIns synthesis
de novo is con¢ned to the ER [21], from which it is trans-
ferred to the nucleus by phosphatidylinositol transfer protein
[21]. In proliferating cells, endonuclear PtdCho synthesis may
provide the necessary capacity for unsaturated endonuclear
DAG removal and or inactivation.
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